查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842012

日本次世代定序市場：市場規模、佔有率和趨勢分析（按技術、產品、應用、工作流程和最終用途分類），細分市場預測（2025-2033 年）

Japan Next Generation Sequencing Market Size, Share & Trends Analysis Report By Technology, By Product, By Application, By Workflow, By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

日本次世代定序市場預計到 2024 年將達到 3.875 億美元，從 2024 年到 2033 年的複合年成長率為 17.24%。

推動這一成長的關鍵因素包括基因定序成本的下降、雲端運算和資料整合技術的顯著進步等。此外，癌症治療領域投資的增加以及次世代定序（NGS）在癌症診斷和治療中的廣泛應用，預計也將進一步推動市場擴張。

癌症發生率上升和精準醫療的發展

日本的癌症發生率和死亡率居世界首位，給其醫療體系帶來了巨大壓力。日益加重的負擔使得日本迫切需要先進的診斷工具，以實現早期檢測、精準的腫瘤表徵和更有效的治療方案。次世代定序（NGS）已成為實現這一目標的關鍵技術，它能夠對腫瘤進行詳細的基因組分析，識別可靶向的突變，並透過液態切片監測疾病進展。 NGS在腫瘤學領域的臨床效用正日益受到日本各大醫院和癌症研究中心的認可，並逐漸廣泛應用於常規癌症診斷。

政府支持的精準醫療計畫正透過推動NGS技術融入主流臨床實踐，進一步加速這一趨勢。例如，厚生舉措省設立的癌症基因組醫學推進計劃等國家級項目，正在全國範圍內建立專門的癌症基因組醫學中心，確保患者能夠公平地獲得先進的定序的診斷技術。此外，越來越多的標靶治療伴隨診斷產品獲得日本監管機構的核准，進一步推動了NGS技術的臨床需求。由於腫瘤學仍然是NGS在日本最大的應用領域，不斷上升的癌症發生率以及政府對精準醫療的重視，都成為市場成長的強勁動力。

政府支持政策和基因組計劃

日本政府透過創造有利的研究和監管環境，在擴大次世代定序（NGS）技術的應用方面發揮關鍵作用。諸如日本基因組醫學計劃和癌症基因組醫學推進計劃等國家級舉措，為大規模基因組研究投入了大量資金，包括基於人群的基因測序計劃和臨床癌症基因組研究。這些計畫旨在促進學術研究，並建立強大的資料庫，為轉化醫學、生物標記發現和新治療方法開發奠定基礎。透過投資建設癌症基因組定序中心和國家生物樣本庫等基礎設施，日本確保研究人員能夠獲得高品質的基因組數據，從而加速疾病機制的發現和個人化治療的研發。

日本的法規結構不斷發展完善，旨在支援新一代定序（NGS）技術快速、順利地融入科學研究和臨床工作流程。日本藥品和醫療設備管理局（PMDA）已為基於NGS的診斷試劑盒和伴隨診斷產品製定了清晰的核准途徑，降低了學術界和產業界研究人員開發新型檢測方法和平台的門檻。這些扶持政策促進了大學、醫院和生技公司之間的合作，建構了一個充滿活力的研究生態系統。政府資助、監管支持和科研機構的積極參與，使日本成為全球NGS研究最密集的市場之一，並使其成為亞洲基因組學主導創新中心。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章：日本次世代定序市場：影響因素、趨勢與範圍

  • 市場關聯性展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 日本次世代定序市場：分析工具
    • SWOT分析：依因素（政治、法律、經濟、技術）進行分析
    • 波特五力分析

第4章：日本次世代定序市場：按技術分類的商業分析

  • 按變異分析和技術分類的次世代定序市場
  • 標靶定序和定序
  • 全基因測序
  • 全EXOME定序

第5章：日本次世代定序市場：按產品分類的業務分析

  • 次世代定序市場：按產品分類的差異分析
  • 平台
  • 消耗品

第6章：日本次世代定序市場：按應用領域分類的業務分析

  • 次世代定序市場：按應用領域分類的變異分析
  • 瘤
  • 臨床研究
  • 生殖健康
  • HLA型檢測/免疫系統監測
  • 總體基因體學、流行病學和藥物研發
  • 農業基因組學與法醫學
  • 消費者基因體學

第7章：日本次世代定序市場：基於工作流程的業務分析

  • 按變異分析和工作流程分類的次世代定序市場
  • 定序前
  • 定序
  • 數據分析

第8章：日本次世代定序市場：按最終用途分類的業務分析

  • 次世代定序市場：基於變異分析和最終用途
  • 學術研究
  • 臨床研究
  • 醫院和診所
  • 製藥和生物技術公司
  • 其他用戶

第9章 競爭情勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 主要企業市場分析（2024 年）
  • 市場參與企業概覽
    • Illumina, Inc
    • QIAGEN
    • Thermo Fisher Scientific, Inc
    • BGI
    • Pacific Biosciences
    • Bio Rad Laboratories
    • Oxford Nanopore Technologies, Inc
    • Myriad Genetics. Inc.
    • Agilent Technologies, Inc.
    • Eurofins Scientific
Product Code: GVR-4-68040-156-5

Market Size & Trends:

The Japan next-generation sequencing market size was valued at USD 387.5 million in 2024 and is projected to grow at a CAGR of 17.24% from 2024 to 2033. Key drivers of this growth include the declining costs associated with genetic sequencing and significant advancements in cloud computing and data integration technologies. Moreover, rising investments in cancer treatment and the broad application of next-generation sequencing (NGS) in cancer diagnosis and therapy are expected to propel market expansion further.

Rising Cancer Burden & Precision Medicine Initiatives

Japan faces some of the highest cancer rates and death rates worldwide, which continue to put a lot of pressure on its healthcare system. This increasing burden creates a strong need for advanced diagnostic tools that allow early detection, accurate characterizations of tumors, and improved treatment choices. Next-generation sequencing (NGS) has become a key technology in this effort, as it enables detailed genomic profiling of tumors, identification of actionable mutations, and monitoring of disease progression through liquid biopsies. The clinical usefulness of NGS in oncology is gaining recognition across Japan's hospitals and cancer research centers, leading to broader adoption in routine cancer diagnostics.

Government-backed precision medicine initiatives further accelerate this trend by promoting the integration of NGS into mainstream clinical practice. National programs like the Cancer Genomic Medicine Program, established by Japan's Ministry of Health, Labour and Welfare, have appointed specialized cancer genome medical centers across the country, ensuring equitable access to advanced sequencing-based diagnostics. Additionally, companion diagnostics for targeted therapies are increasingly gaining approval from Japan's regulatory authorities, which boosts the clinical demand for NGS technologies. Since oncology remains the largest application area for NGS in Japan, the combined effect of rising cancer rates and supportive government precision medicine efforts is a strong driver of market growth.

Supportive Government Policies & Genomic Programs

The Japanese government has played a key role in increasing the use of next-generation sequencing (NGS) technologies by creating a supportive research and regulatory environment. National initiatives like the Japan Genomic Medicine Program and the Cancer Genomic Medicine Promotion Plan have allocated significant funding for large-scale genomic research, including population-based genome sequencing projects and clinical cancer genome studies. These programs aim to boost academic research and develop strong databases that form the basis for translational medicine, biomarker discovery, and new therapeutic development. By investing in infrastructure such as cancer genome sequencing centers and national biobanks, Japan enables researchers to access high-quality genomic data that speed up discoveries in disease mechanisms and personalized treatments.

The country's regulatory framework has progressed to support faster and smoother integration of NGS into research and clinical workflows. The Pharmaceuticals and Medical Devices Agency (PMDA) has established clear approval pathways for NGS-based diagnostic panels and companion diagnostics, lowering barriers for academic groups and industry researchers to develop new assays and platforms. These supportive policies foster collaborations among universities, hospitals, and biotechnology companies, creating a thriving research ecosystem. The alignment of government funding, regulatory support, and institutional participation makes Japan one of the most research-intensive markets for NGS worldwide, establishing it as a hub for genomics-driven innovation in Asia.

Japan Next Generation Sequencing Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the Japan next generation sequencing market on the basis of technology, product, end use, workflow, and application:

  • Technology Outlook (Revenue in USD Million, 2021 - 2033)
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Resequencing
    • DNA-based
    • RNA-based
  • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Consumables
    • Sample Preparation
    • Target Enrichment
  • Platforms
    • Sequencing
    • Data Analysis
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
    • Diagnostics and Screening
    • Oncology Screening
    • Sporadic Cancer
    • Inherited Cancer
    • Companion Diagnostics
    • Other Diagnostics
    • Research Studies
  • Clinical Investigation
    • Infectious Diseases
    • Inherited Diseases
    • Idiopathic Diseases
    • Non-Communicable/Other Diseases
  • Reproductive Health
    • NIPT
    • Aneuploidy
    • Microdeletions
    • PGT
    • Newborn Genetic Screening
    • Single Gene Analysis
  • HLA Typing/Immune System Monitoring
  • Metagenomics, Epidemiology & Drug Development
  • Agrigenomics & Forensics
  • Consumer Genomics
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Pre-Sequencing
    • Nucleic Acid Extraction
    • Library Preparation
  • Sequencing
  • NGS Data Analysis
    • NGS Primary Data Analysis
    • NGS Secondary Data Analysis
    • NGS Tertiary Data Analysis
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharma & Biotech Entities
  • Other users

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Technology
    • 1.1.2. Product
    • 1.1.3. Application
    • 1.1.4. Workflow
    • 1.1.5. End Use
    • 1.1.6. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights

Chapter 3. Japan Next Generation Sequencing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising cancer burden & precision medicine initiatives
      • 3.2.1.2. Supportive government policies & genomic programs
      • 3.2.1.3. Rise in competition among prominent market entities
      • 3.2.1.4. Rising clinical opportunity for NGS technology
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of computational efficiency for data management
      • 3.2.2.2. Non-value-based NGS reimbursement policy and regulation status
      • 3.2.2.3. Challenges associated with NGS implementation.
  • 3.3. Japan Next Generation Sequencing Market Analysis Tools
    • 3.3.1. SWOT analysis; by factor (political & legal, economic, and technological)
    • 3.3.2. Porter's Five Forces Analysis

Chapter 4. Japan Next Generation Sequencing Market: Technology Business Analysis

  • 4.1. Next Generation Sequencing Market: Technology Movement Analysis
  • 4.2. Targeted Sequencing & Resequencing
    • 4.2.1. Targeted Sequencing & Resequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
      • 4.2.1.1. DNA-based targeted sequencing & resequencing
        • 4.2.1.1.1. DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
      • 4.2.1.2. RNA-based targeted sequencing & resequencing
        • 4.2.1.2.1. RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • 4.3. Whole Genome Sequencing
    • 4.3.1. Whole Genome Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 4.4. Whole Exome Sequencing
    • 4.4.1. Whole Exome Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 5. Japan Next Generation Sequencing Market: Product Business Analysis

  • 5.1. Next Generation Sequencing Market: Product Movement Analysis
  • 5.2. Platforms
    • 5.2.1. Platforms Market Estimates And Forecast, 2021 - 2033 (USD Million)
      • 5.2.1.1. Sequencing
        • 5.2.1.1.1. Sequencing platforms market estimates and forecast, 2021 - 2033 (USD Million)
      • 5.2.1.2. Data Analysis
        • 5.2.1.2.1. Data analysis platforms market estimates and forecast, 2021 - 2033 (USD Million
  • 5.3. Consumables
    • 5.3.1. Consumables market estimates and forecast, 2021 - 2033 (USD million)
    • 5.3.2. Sample Preparation
      • 5.3.2.1. Sample preparation market estimates and forecast, 2021 - 2033 (USD Million)
    • 5.3.3. Target Enrichment
      • 5.3.3.1. Target enrichment market estimates and forecast, 2021 - 2033 (USD Million)
    • 5.3.4. Others
      • 5.3.4.1. Others market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 6. Japan Next Generation Sequencing Market: Application Business Analysis

  • 6.1. Next Generation Sequencing Market: Application Movement Analysis
  • 6.2. Oncology
    • 6.2.1. Oncology Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 6.2.2. Diagnostics & Screening
      • 6.2.2.1. Diagnostics & screening market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.2.2.2. Oncology screening
        • 6.2.2.2.1. Oncology screening market estimates and forecast, 2021 - 2033 (USD Million)
        • 6.2.2.2.2. Sporadic cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
        • 6.2.2.2.3. Inherited cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.2.2.3. Companion diagnostics
        • 6.2.2.3.1. Companion diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.2.2.4. Other diagnostics
        • 6.2.2.4.1. Other diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.2.3. Research Studies
      • 6.2.3.1. Research studies market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.3. Clinical investigation
    • 6.3.1. Clinical investigation market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.2. Infectious Diseases
      • 6.3.2.1. Infectious diseases market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.3. Idiopathic Diseases
      • 6.3.3.1. Idiopathic diseases market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.4. Inherited Diseases
      • 6.3.4.1. Inherited diseases market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.3.5. Non-Communicable/Other Diseases
      • 6.3.5.1. Non-communicable/other diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.4. Reproductive Health
    • 6.4.1. Reproductive Health Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 6.4.2. NIPT
      • 6.4.2.1. NIPT market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.4.2.2. Aneuploidy
        • 6.4.2.2.1. Aneuploidy market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.4.2.3. Microdeletions
        • 6.4.2.3.1. Microdeletions market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.3. PGT
      • 6.4.3.1. PGT market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.4. Newborn Genetic Screening
      • 6.4.4.1. Newborn genetic screening market estimates and forecast, 2021 - 2033 (USD Million)
    • 6.4.5. Single Gene Analysis
      • 6.4.5.1. Single gene analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5. HLA Typing/Immune System Monitoring
    • 6.5.1. HLA Typing/Immune System Monitoring Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.6. Metagenomics, Epidemiology & Drug Development
    • 6.6.1. Metagenomics, Epidemiology & Drug Development Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.7. Agrigenomics & Forensics
    • 6.7.1. Agrigenomics & Forensics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.8. Consumer Genomics
    • 6.8.1. Consumer Genomics Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 7. Japan Next Generation Sequencing Market: Workflow Business Analysis

  • 7.1. Next Generation Sequencing Market: Workflow Movement Analysis
  • 7.2. Presequencing
    • 7.2.1. Pre-Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
      • 7.2.1.1. Nucleic Acid Extraction
        • 7.2.1.1.1. Nucleic acid extraction market estimates and forecast, 2021 - 2033 (USD Million)
      • 7.2.1.2. Library Preparation
        • 7.2.1.2.1. Library preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.3. Sequencing
    • 7.3.1. Sequencing Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.4. Data Analysis
    • 7.4.1. Data Analysis Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.4.2. Primary Data NGS Analysis
      • 7.4.2.1. Primary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.3. Secondary Data Analysis
      • 7.4.3.1. Secondary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.4.4. Tertiary Data Analysis
      • 7.4.4.1. Tertiary data analysis market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 8. Japan Next Generation Sequencing Market: End Use Business Analysis

  • 8.1. Next Generation Sequencing Market: End Use Movement Analysis
  • 8.2. Academic Research
    • 8.2.1. Academic Research Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.3. Clinical Research
    • 8.3.1. Clinical Research Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.4. Hospitals & Clinics
    • 8.4.1. Hospitals & Clinics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.5. Pharmaceutical & Biotech Entities
    • 8.5.1. Pharmaceutical & Biotech Entities Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.6. Other Users
    • 8.6.1. Other Users Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Key Company Market Position Analysis, 2024
  • 9.4. Participants Overview
    • 9.4.1. Illumina, Inc
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. QIAGEN
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Thermo Fisher Scientific, Inc
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. BGI
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Pacific Biosciences
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Bio Rad Laboratories
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Oxford Nanopore Technologies, Inc
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Myriad Genetics. Inc.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Agilent Technologies, Inc.
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Eurofins Scientific
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Japan next generation sequencing market, by technology, 2021 - 2033 (USD Million)
  • Table 4 Japan next generation sequencing market, by product, 2021 - 2033 (USD Million)
  • Table 5 Japan next generation sequencing market, by application, 2021 - 2033 (USD Million)
  • Table 6 Japan next generation sequencing market, by workflow, 2021 - 2033 (USD Million)
  • Table 7 Japan next generation sequencing market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Japan next generation sequencing market: market outlook
  • Fig. 7 Japan next generation sequencing competitive insights.
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 Japan next generation sequencing market driver impact
  • Fig. 11 Japan next generation sequencing market restraint impact
  • Fig. 12 Japan next generation sequencing market: Technology movement analysis
  • Fig. 13 Japan next generation sequencing market: Technology outlook and key takeaways
  • Fig. 14 Targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 15 DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 16 RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 Whole genome sequencing market estimates and forecast, 2021-2033 (USD Million)
  • Fig. 18 Whole exome sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 Japan Next-generation sequencing market: Product outlook key takeaways
  • Fig. 20 Japan Next-generation sequencing market: Product movement analysis
  • Fig. 21 Platforms market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Sequencing platforms market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Data analysis platforms market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Consumables market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Sample preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Target enrichment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Japan next generation sequencing Market: Application Movement Analysis
  • Fig. 29 Japan next generation sequencing market: Application outlook and key takeaways
  • Fig. 30 Oncology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Diagnostics & screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Oncology screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Sporadic cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Inherited cancer screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Companion diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 Other diagnostics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 37 Research studies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Clinical investigation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Infectious diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Idiopathic diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Inherited diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 42 Non-communicable/other diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 43 Reproductive health market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 NIPT market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Aneuploidy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Microdeletions market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 47 PGT market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Newborn genetic screening market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 49 Single gene analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 HLA typing/immune system monitoring market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 51 Metagenomics, epidemiology & drug development market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Agrigenomics & forensics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 53 Consumer genomics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Japan next generation sequencing market: workflow movement analysis
  • Fig. 55 Japan next generation sequencing market: workflow outlook and key takeaways
  • Fig. 56 Pre-sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 57 Nucleic acid extraction market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 58 Library preparation market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 59 Sequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 Data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 61 Primary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Secondary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 63 Tertiary data analysis market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 64 Japan Next generation sequencing market End Use outlook key takeaways
  • Fig. 65 Japan Next-generation sequencing market: End Use movement analysis
  • Fig. 66 Academic research market estimates and forecast, 2021 - 2033 (USD Million))
  • Fig. 67 Clinical research market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 Hospitals & clinics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 69 Pharmaceutical & biotech entities market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 70 Other users market estimates and forecast, 2021 - 2033 (USD Million)